AQP9 Protein Identified as Potential Target for Alcohol Liver Disease Treatment

Researchers have identified the protein aquaporin 9 (AQP9) as a potential therapeutic target for the treatment of alcohol use disorder and advanced alcohol-associated liver disease. The findings, published on April 8, 2026, in the journal Alcohol: Clinical and Experimental Research, suggest that this protein plays a critical role in how the body processes the toxic byproducts of alcohol consumption.

AQP9 is involved in the transport of acetaldehyde, a byproduct of alcohol metabolism that can be toxic to the body. Specifically, the protein regulates the influx of acetaldehyde into hepatocytes, which are the primary functional cells of the liver.

By controlling this influx, AQP9 helps coordinate the clearance of acetaldehyde at both the hepatic and systemic levels. This mechanism is a key determinant of how alcohol is metabolized and the extent to which the liver suffers injury during the process.

Impact on Liver Injury and Disease Progression

The research indicates that the presence and activity of AQP9 significantly influence the progression of alcohol-associated liver disease. In studies focusing on the early stages of the condition, researchers found that a deficiency in AQP9 actually mitigates early alcohol-associated liver disease.

However, the expression of the protein changes as the disease becomes more severe. Data shows that in patients with severe alcohol-associated hepatitis, liver AQP9 expression is downregulated at both the gene and protein levels.

This suggests a complex relationship where the protein’s role in transporting acetaldehyde can both contribute to and be affected by the severity of liver damage.

Influence on Drinking Behavior

Beyond its physiological effects on liver tissue, AQP9 also appears to influence behavioral patterns related to alcohol use. The study found that AQP9 bidirectionally modulates alcohol consumption.

Because AQP9-regulated acetaldehyde transport determines both alcohol metabolism and drinking behavior, it represents a dual-action target for medical intervention. This makes the protein a point of interest for those seeking treatments that address both the physical damage of liver disease and the behavioral aspects of alcohol use disorder.

The ability of AQP9 to regulate the movement of toxic byproducts into the liver suggests that modulating this protein could potentially limit the damage caused by alcohol while simultaneously influencing the drive to consume alcohol.

Therapeutic Potential

The identification of AQP9 as a regulator of acetaldehyde influx provides a new pathway for developing therapies. Because the protein is central to the coordination of systemic and hepatic clearance of toxins, We see viewed as a viable target for treating advanced stages of liver disease.

By targeting AQP9, researchers hope to find ways to better manage the toxic effects of alcohol metabolism and provide new options for patients struggling with alcohol use disorder and its associated hepatic complications.